Delivery Order SPE2DB22D2103-SPE2DB25FR9BP

Award Date 4/7/25
Potential Completion Date 4/8/25
Potential Value $2.7K
Ultimate Awardee
Not listed
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
Conshohocken, PA 19428, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
Not listed
Legislative Mandate
Not listed
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
This is a federal contract award from the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract, valued at $1,577.04, is for the delivery of QUILLIVANT XR 25 MG/5 ML SUSP 60ML, a pharmaceutical product. The contract has an ultimate completion date of April 2, 2025. This award is a delivery order under a larger Indefinite Delivery Contract (IDC) held by AmerisourceBergen with the DLA Troop Support Medical,...
This federal contract award, valued at $1,942.84, was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the supply of QUILLIVANT XR 25 MG/5 ML SUSP 180ML, a pharmaceutical product, and is a Delivery Order under an Indefinite Delivery Contract (IDC) held by AmerisourceBergen with the DLA. The IDC, valued at $999,999,999, serves as a primary vehicle for providing a comprehensive...
This is a $1,550.28 firm fixed price delivery order awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the supply of QUILLIVANT XR 25 MG/5 ML SUSP 60ML, a pharmaceutical product, with a completion date of March 17, 2025. This award is part of a larger Indefinite Delivery Contract (IDC) valued at $999,999,999 that AmerisourceBergen holds with the DLA Troop Support Medical, which...
This is a firm fixed-price delivery order contract awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract, valued at $2,196.51, is for the supply of QUILLIVANT XR 25 MG/5 ML SUSP 180ML, a pharmaceutical product. The contract has an ultimate completion date of March 31, 2025. This contract award is part of a larger Indefinite Delivery Contract (IDC) that AmerisourceBergen holds with the DLA...
This federal contract award was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $1,850.42 Firm Fixed Price Delivery Order contract is for the supply of QUILLIVANT XR 25 MG/5 ML SUSP 120ML, a specialty medication. The contract has an ultimate completion date of October 25, 2024. This appears to be a task order issued under a larger Indefinite Delivery Contract (IDC) that AmerisourceBergen...
This is a delivery order contract awarded by the Defense Logistics Agency (DLA) Troop Support Medical to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract, valued at $5,075.09, is for the supply of QUILLIVANT XR ORAL SUSP 60ML 5MG/ML, a medication used in the treatment of medical conditions. The contract has a firm fixed price pricing type and an ultimate completion date of January 9, 2024. This delivery order is part of a larger...
This federal contract award from the Defense Logistics Agency (DLA) was issued to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $5,298.59 Firm Fixed Price Delivery Order contract is for the supply of QUILLIVANT XR 25 MG/5 ML SUSP 180ML, a prescription medication. The award is associated with a larger Indefinite Delivery Contract (IDC) valued at $999,999,999 that AmerisourceBergen holds with the DLA Troop Support Medical, which serves as...
This is a $2,887.63 firm fixed-price delivery order contract awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor. The contract is for the supply of QUILLIVANT XR 25 MG/5 ML SUSP 180ML, a medication, and does not have a set-aside designation. AmerisourceBergen holds a $999,999,999 Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, which serves as a primary vehicle for providing a comprehensive range of pharmaceutical...
This is a firm fixed-price delivery order contract awarded by the Defense Logistics Agency (DLA) Troop Support Medical to AmerisourceBergen Drug Corp, a major pharmaceutical distributor. The contract, valued at $5,019.01, is for the supply of QUILLIVANT XR ORAL SUSP 180ML 5MG/ML, a pharmaceutical product. The contract has an ultimate completion date of March 27, 2025. This delivery order is part of a larger Indefinite Delivery Contract (IDC) valued at $999,999,999 that AmerisourceBergen holds...
This is a firm fixed-price delivery order contract awarded by the Defense Logistics Agency (DLA) Troop Support Medical to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract, valued at $3,698.72, is for the supply of QUILLIVANT XR 25 MG/5 ML SUSP 180ML, a specialty medication. The contract has an ultimate completion date of January 17, 2024. This delivery order is part of a larger Indefinite Delivery Contract (IDC) that...
  • SPE2DB22D2103
    Indefinite Delivery Contract
  • SPE2DB22D2103-SPE2DB25FR9BP
    Delivery Order

This is a federal contract award from the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract, valued at $2,734.66, is for the supply of QUILLIVANT XR 25 MG/5 ML SUSP 150ML, a prescription medication. The contract is a Delivery Order under a larger Indefinite Delivery Contract (IDC) valued at $999,999,999 between AmerisourceBergen and the DLA Troop Support Medical, which serves as a primary vehicle for providing a comprehensive range of pharmaceutical products and medical supplies to support military healthcare programs globally. The contract has a firm fixed price and an ultimate completion date of April 8, 2025. The contract did not have a set-aside designation, indicating open competition.

Generated 7/7/25, 1:24 PM